Idiopathic Pulmonary Fibrosis Market - Global Forecast 2026-2032

The idiopathic pulmonary fibrosis market continues to transform, marked by advances in therapeutic approaches, evolving care delivery models, and a growing need for operational agility. Senior decision-makers must leverage actionable market intelligence to adapt to regulatory shifts, optimize strategies, and secure sustainable growth in a challenging environment.

Market Snapshot: Idiopathic Pulmonary Fibrosis Market

The Idiopathic Pulmonary Fibrosis Market is projected to grow from USD 4.19 billion in 2025 to USD 4.42 billion in 2026, with an anticipated CAGR of 5.71%. By 2032, forecasts position the market value at USD 6.19 billion. This steady pace of expansion is driven by broader adoption of antifibrotic therapies, improvements in diagnostic technologies, and increasing implementation of patient-centric care models. Ongoing clinical progress, dynamic payer behavior, and enhanced supply-chain strategies continue to reinforce the market's momentum.

Scope & Segmentation

Therapeutic Classes: Antifibrotic agents, including nintedanib and pirfenidone, remain principal therapies. Corticosteroids are applied for acute interventions, while immunomodulators address select patient populations to complement existing standards.
Routes of Administration: Oral therapies are fundamental for maintenance, with expanding interest in inhaled options and targeted use of injectable formulations for specific clinical scenarios.
Distribution Channels: Hospital and specialty pharmacies cater to complex treatment needs. Retail and online outlets improve accessibility for stable cases, and home healthcare supports long-term patient management.
End-User Settings: Hospitals and specialty clinics are central to initial diagnosis and treatment initiation. Ambulatory centers and home care increasingly facilitate ongoing disease monitoring and patient support.
Regional Dynamics: Coverage includes the Americas, Europe, the Middle East & Africa, and Asia-Pacific. Each region displays unique reimbursement frameworks, launch methodologies, and partnership requirements, informing tailored approaches.
Technology Integration: Remote monitoring, digital biomarkers, and telehealth tools are reshaping adherence strategies and modernizing care delivery pathways for improved outcomes.

Key Takeaways for Senior Decision-Makers

Emerging innovations are moving the therapeutic landscape from symptomatic support toward targeted, disease-modifying treatments, requiring sophisticated market differentiation and evidence-driven positioning.
Integrated care models and decentralized service pathways are on the rise, amplifying the significance of multidisciplinary clinics and home-based intervention in strategic planning.
Healthcare payers are increasing their demands for demonstrable value through real-world outcomes, particularly reductions in hospitalization and proven enhancements in patient quality of life.
Operational resilience and robust supply-chain frameworks are becoming decisive advantages as companies navigate external volatility and strive to maintain continuous product access.
Regional variations in regulatory and reimbursement environments drive the need for localized launch strategies, partnership models, and compliance considerations throughout the product lifecycle.
Pipeline strategies now increasingly emphasize patient engagement programs and digital health adoption, helping to drive adherence, optimize long-term outcomes, and reinforce market engagement.

Tariff Impact Across the Idiopathic Pulmonary Fibrosis Value Chain

Recent changes in tariffs and global trade policies are introducing additional complexities in sourcing and distributing pharmaceuticals. Heightened duties on active ingredients or finished products are pushing companies to reevaluate their supplier networks, contemplate increased regional manufacturing, and renegotiate long-term procurement contracts to manage cost exposures. This has prompted healthcare systems and payers to scrutinize formularies and contracting practices, intensifying the imperative for transparent value demonstration and operational adaptability at every stage of the supply chain.

Methodology & Data Sources

This report employs a rigorous mixed-methods process, integrating comprehensive analysis of peer-reviewed clinical literature, regulatory documentation, and clinical trial data with direct insights from pulmonologists, specialty pharmacists, and health economics experts. Scenario modeling and supply-chain analyses enhance the balanced view. All research adheres to established ethical and quality standards, ensuring actionable intelligence for informed decision-making.

Why This Report Matters

Enables strategic planning by condensing key clinical, commercial, and operational market signals into clear, actionable guidance for investment and go-to-market initiatives.
Empowers senior leaders to proactively address risks while capitalizing on evolving opportunities, aligning supply-chain, access, and product strategies with new market drivers.
Provides in-depth segmentation and regional perspectives, supporting the development of tailored commercialization, pricing, and partnership approaches across varied global settings.

Conclusion

The market for idiopathic pulmonary fibrosis requires a coordinated strategy that aligns clinical progress, operational strength, and value communication. Organizations that synchronize these elements will be best equipped to improve patient care and sustain long-term commercial performance.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Idiopathic Pulmonary Fibrosis Market, by Therapeutic Class

8.1. Antifibrotics
8.1.1. Nintedanib
8.1.2. Pirfenidone
8.2. Immunosuppressants
8.2.1. Corticosteroids
8.2.1.1. Methylprednisolone
8.2.1.2. Prednisone
8.2.2. Immunomodulators
8.2.2.1. Azathioprine
8.2.2.2. Mycophenolate Mofetil

9. Idiopathic Pulmonary Fibrosis Market, by Route Of Administration

9.1. Inhalation
9.2. Injectable
9.3. Oral

10. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies
10.4. Specialty Pharmacies

11. Idiopathic Pulmonary Fibrosis Market, by End User

11.1. Ambulatory Care Centers
11.2. Home Healthcare Facilities
11.3. Hospitals
11.4. Specialty Clinics

12. Idiopathic Pulmonary Fibrosis Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Idiopathic Pulmonary Fibrosis Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Idiopathic Pulmonary Fibrosis Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Idiopathic Pulmonary Fibrosis Market
16. China Idiopathic Pulmonary Fibrosis Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AstraZeneca PLC
17.6. Boehringer Ingelheim International GmbH
17.7. Bristol-Myers Squibb Company
17.8. F. Hoffmann-La Roche Ltd.
17.9. Galapagos NV
17.10. Gilead Sciences, Inc.
17.11. Glenmark Pharmaceuticals Ltd.
17.12. GNI Group Ltd.
17.13. Horizon Therapeutics PLC by Amgen Inc.
17.14. Johnson & Johnson
17.15. Lupin Ltd.
17.16. Merck & Co., Inc.
17.17. Novartis AG
17.18. Pfizer Inc.

List of Figures

FIGURE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 112. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 116. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 130. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 132. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 133. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 134. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 149. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 150. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 151. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 152. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 153. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 158. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 159. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 160. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 161. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 162. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 164. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 175. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 176. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 177. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 178. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 179. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 180. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 185. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 186. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 187. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 188. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 189. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 194. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 195. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 196. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 197. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 198. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 213. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
TABLE 214. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
TABLE 215. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 216. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 217. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 218. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 219. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Idiopathic Pulmonary Fibrosis market report include:

AstraZeneca PLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Galapagos NV
Gilead Sciences, Inc.
Glenmark Pharmaceuticals Ltd.
GNI Group Ltd.
Horizon Therapeutics PLC by Amgen Inc.
Johnson & Johnson
Lupin Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

Table Information

Report Attribute	Details
No. of Pages	180
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 4.42 Billion
Forecasted Market Value ( USD ) by 2032	$ 6.19 Billion
Compound Annual Growth Rate	5.7%
Regions Covered	Global
No. of Companies Mentioned	15

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Idiopathic Pulmonary Fibrosis Market

Scope & Segmentation

Key Takeaways for Senior Decision-Makers

Tariff Impact Across the Idiopathic Pulmonary Fibrosis Value Chain

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Idiopathic Pulmonary Fibrosis Market Report: Trends, Forecast and Competitive Analysis to 2031

Idiopathic Pulmonary Fibrosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Pulmonary Fibrosis Treatment - Global Strategic Business Report

Idiopathic Pulmonary Fibrosis - Global Strategic Business Report

Idiopathic Pulmonary Fibrosis Market Report 2025